Joseph John N, Deaton David, Ehsan Houman, Bonanno Mark A
Civil Division, U.S. Attorney's Office, Eastern District of Pennsylvania, USA.
J Health Life Sci Law. 2009 Jan;2(2):73-108.
Off-label drug or medical device "use" is the practice of prescribing drugs or medical devices to patients for a purpose not included on the federally approved label. Off-label "marketing" is the practice of attempting to influence physicians to prescribe drugs or devices for off-label purposes. The federal Food and Drug Administration (FDA) maintains regulatory authority over the proper labeling of drugs and medical devices. Although not illegal, off-label use of certain drugs has led to controversy in recent years, especially in light of alleged behind-the-scenes marketing practices intended to increase off-label prescribing. Off-label marketing practices are prohibited and could result in criminal charges against a manufacturer, depending upon the circumstances. Yet a vast gray area exists for subtle marketing practices, such as circulating published medical studies about off-label uses to physicians. This article summarizes the legal and medical standards associated with off-label use and marketing of drugs, provides summaries of recent enforcement activities regarding off-label marketing, and explains the current federal regulatory issues surrounding off-label marketing practices. The authors provide practical pointers on regulatory compliance and the risks associated with fraud and abuse laws for drug companies and practitioners.
药品或医疗器械的“非标签使用”是指医生为患者开具药品或医疗器械时,其目的未包含在联邦批准的标签范围内。“非标签营销”是指试图影响医生为非标签目的开具药品或器械的行为。联邦食品药品监督管理局(FDA)对药品和医疗器械的正确标签拥有监管权。尽管某些药品的非标签使用并不违法,但近年来已引发争议,特别是鉴于存在旨在增加非标签处方的所谓幕后营销行为。非标签营销行为被禁止,视具体情况可能导致对制造商的刑事指控。然而,对于一些微妙的营销行为,比如向医生散发有关非标签用途的已发表医学研究报告,却存在很大的灰色地带。本文总结了与药品非标签使用和营销相关的法律及医学标准,提供了近期有关非标签营销执法活动的概述,并解释了围绕非标签营销行为目前存在的联邦监管问题。作者为制药公司和从业者提供了有关监管合规以及与欺诈和滥用法律相关风险的实用指南。